Daniel Allen Gold - Sep 10, 2024 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
Director
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Daniel Gold
Stock symbol
ROIV
Transactions as of
Sep 10, 2024
Transactions value $
$0
Form type
4
Date filed
9/12/2024, 09:00 PM
Previous filing
Mar 7, 2024
Next filing
Sep 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Award $0 +16.4K +0.23% $0.00 7.29M Sep 10, 2024 Direct F1
holding ROIV Common Shares 2.66M Sep 10, 2024 Held by trusts and estate planning vehicles established by the Reporting Person F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Award $0 +27.9K $0.00 27.9K Sep 10, 2024 Common Shares 27.9K $12.19 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date.
F2 The reporting person is a trustee of trusts and estate planning vehicles, each of which were formed by the reporting person and/or his immediate family members and shares voting and investment control over the Common Shares held directly by these trusts and may be deemed to beneficially own such Common Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
F3 Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date.